S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end

Barinthus Biotherapeutics (BRNS) Short Interest Ratio & Short Volume

$2.51
-0.20 (-7.38%)
(As of 04/19/2024 ET)

Barinthus Biotherapeutics Short Interest Data

Current Short Volume
10,100 shares
Previous Short Volume
11,900 shares
Change Vs. Previous Month
-15.13%
Dollar Volume Sold Short
$24,038.00
Short Interest Ratio / Days to Cover
0.5
Last Record Date
March 31, 2024
Outstanding Shares
38,920,000 shares
Float Size
35,310,000 shares
Short Percent of Float
0.03%
Today's Trading Volume
3,441 shares
Average Trading Volume
35,833 shares
Today's Volume Vs. Average
10%
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Barinthus Biotherapeutics ?

Sign up to receive the latest short interest report for Barinthus Biotherapeutics and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

BRNS Short Interest Over Time

BRNS Days to Cover Over Time

BRNS Percentage of Float Shorted Over Time

Barinthus Biotherapeutics Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
3/31/202410,100 shares $24,038.00 -15.1%0.0%0.5 $2.38
3/15/202411,900 shares $29,393.00 -3.3%0.0%0.8 $2.47
2/29/202412,300 shares $34,809.00 -12.8%0.0%0.8 $2.83
2/15/202414,100 shares $34,968.00 -55.8%0.0%1.2 $2.48
1/31/202431,900 shares $87,725.00 No Change0.1%1.3 $2.75

BRNS Short Interest - Frequently Asked Questions

What is Barinthus Biotherapeutics' current short interest?

Short interest is the volume of Barinthus Biotherapeutics shares that have been sold short but have not yet been closed out or covered. As of March 31st, traders have sold 10,100 shares of BRNS short. 0.03% of Barinthus Biotherapeutics' shares are currently sold short. Learn More on Barinthus Biotherapeutics' current short interest.

What is a good short interest percentage for Barinthus Biotherapeutics?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.03% of Barinthus Biotherapeutics' floating shares are currently sold short.

Is Barinthus Biotherapeutics' short interest increasing or decreasing?

Barinthus Biotherapeutics saw a drop in short interest in March. As of March 31st, there was short interest totaling 10,100 shares, a drop of 15.1% from the previous total of 11,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Barinthus Biotherapeutics' float size?

Barinthus Biotherapeutics currently has issued a total of 38,920,000 shares. Some of Barinthus Biotherapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Barinthus Biotherapeutics currently has a public float of 35,310,000 shares.

How does Barinthus Biotherapeutics' short interest compare to its competitors?

0.03% of Barinthus Biotherapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Barinthus Biotherapeutics: NGM Biopharmaceuticals, Inc. (4.52%), Vaccitech plc (0.45%), Nuvectis Pharma, Inc. (12.12%), Eliem Therapeutics, Inc. (0.07%), Citius Pharmaceuticals, Inc. (7.81%), Immunic, Inc. (3.37%), Coya Therapeutics, Inc. (1.53%), Annovis Bio, Inc. (13.62%), FibroGen, Inc. (5.65%), Adagene Inc. (0.04%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks.

What does it mean to sell short Barinthus Biotherapeutics stock?

Short selling BRNS is an investing strategy that aims to generate trading profit from Barinthus Biotherapeutics as its price is falling. BRNS shares are trading down $0.20 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Barinthus Biotherapeutics?

A short squeeze for Barinthus Biotherapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of BRNS, which in turn drives the price of the stock up even further.

How often is Barinthus Biotherapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BRNS, twice per month. The most recent reporting period available is March, 31 2024.



More Short Interest Resources from MarketBeat

This page (NASDAQ:BRNS) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners